---
document_datetime: 2023-09-21 20:16:46
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/vocabria-epar-all-authorised-presentations_en.pdf
document_name: vocabria-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 1.0389246
conversion_datetime: 2025-12-15 23:02:30.380476
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## Annex A

<div style=\"page-break-after: always\"></div>

| MA (EU) number   | (Invented) name   | Strength   | Pharmaceutical Form                        | Route of Administration   | Immediate Packaging   | Content (concentration)   | Pack size                                      |
|------------------|-------------------|------------|--------------------------------------------|---------------------------|-----------------------|---------------------------|------------------------------------------------|
| EU/1/20/1481/001 | VOCABRIA          | 30 mg      | Film-coated tablet                         | Oral use                  | bottle (HDPE)         |                           | 30 tablets                                     |
| EU/1/20/1481/002 | VOCABRIA          | 400 mg     | Prolonged-release suspension for injection | Intramuscular use         | vial (glass)          | 2 ml (200 mg/ml)          | 1 vial + 1 syringe + 1 vial adapter + 1 needle |
| EU/1/20/1481/003 | VOCABRIA          | 600 mg     | Prolonged-release suspension for injection | Intramuscular use         | vial (glass)          | 3 ml (200 mg/ml)          | 1 vial + 1 syringe + 1 vial adapter + 1 needle |